Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke

BACKGROUND: The objective of the study was to assess the cost‐effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke. METHODS AND RESULTS: A Markov model decision tree was used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lily W., Kraler, Lironn, de Havenon, Adam, Lansberg, Maarten G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238703/
https://www.ncbi.nlm.nih.gov/pubmed/35656996
http://dx.doi.org/10.1161/JAHA.121.024992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238703/
https://www.ncbi.nlm.nih.gov/pubmed/35656996
http://dx.doi.org/10.1161/JAHA.121.024992

Ejemplares similares